Clinical trial · Interventional
Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC
Neo-Sequence 2：Phase 2 Study of Neoadjuvant Chemotherapy Plus Anti-angiogenesis Therapy and Immunotherapy for Locally Advanced Diffuse Gastric Cancer
NCT06371586CI-TRIAL-00076190recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The regimen of Albumin paclitaxel+SOX+BEV neoadjuvant therapy lasted for 6 cycles, during which PD-1 monoclonal antibody therapy was interspersed for 4 cycles for locally advanced diffuse gastric cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Type Carcinoma | Gastric Neoplasm | PROBABILISTIC | 0.70 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Experimental arm
- description
- Neoadjuvant Chemotherapy Plus Anti-angiogenesis Therapy and Immunotherapy
- interventionNames
- Drug: Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy
Primary outcomes (1)
- measure
- Pathological response rate
- timeFrame
- 3 year
- description
- No residual cancer cells
Secondary outcomes (4)
- measure
- EFS
- timeFrame
- 3 year
- description
- event free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Local advanced diffuse or mixed type gastric cancer detected by pathology and endoscopy; 2. Chest, abdomen, and pelvis enhanced CT, neck and supraclavicular ultrasound, gastroscopy, and endoscopic ultrasound were used to diagnose T3-4NanyM0 gastric cancer or gastroesophageal junction cancer (refer to AJCC staging, 8th edition); 3. Has not received any anti-tumor treatment for gastric cancer yet; 4. Age range from 18 to 75 years old; 5. ECOG score 0-1 points; 6. Liver and kidney function and blood routine meet the following conditions: Neutrophils\>1.5G/L, Hb\>90g/L, PLT\>100G/L; ALT and AST\<2.5ULN; TBIL\<1.5 ULN; Cr\<1.0ULN; 7. Left ventricular ejection fraction\>60%; 8. Good compliance and ability to accept long-term follow-up; 9. Sign informed consent. Exclusion Criteria: 1. Gastrointestinal obstruction or recurrent bleeding cannot be controlled; 2. Those who cannot swallow pills; 3. Diagnose immunodeficiency or active autoimmune diseases, have received or are currently receiving immunomodulators, systemic steroid therapy, or immunosuppressive drugs within the past two years; 4. Interstitial pneumonia; 5. Moderate to severe cirrhosis caused by any reason; 6. Uncontrollable hypertension, severe kidney disease, and significant cardiovascular and cerebrovascular diseases; 7. Active infections that require systemic treatment; 8. Previously suffered from other tumors, excluding cured skin cancer and cervical cancer in situ; 9. Internal medicine diseases that do not meet the chemotherapy criteria at the same time; 10. Pregnant and lactating patients; 11. Individuals with a history of mental illness and poor compliance.
References
Publications (0)
Data not yet available
No reference posted for this study.